C9-T Immunity Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
- Coordinator
- Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV, Germany
- Runs
- 1 April 2024 to 31 March 2029
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101117710
What the project is doing
In the project's own words, from its summary on CORDIS.
Neurodegenerative diseases are the top 3 leading causes of death and are viewed now as systemic diseases. Adaptive immunity including a T-cell response in the central nervous system (CNS) likely contributes to disease pathogenesis. How T cells are primed and recruited to CNS is largely unexplored, due to the complexity of the process and lack of tools and animal models. I will study these questions on the most common genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Here, a GGGGCC repeat expansion in the C9orf72 gene causes haploinsufficiency through reduced C9orf72 protein expression, and gain-of-function toxicities through repeat RNA and its translation to aggregating dipeptide repeats (DPRs). A synergistic role of these pathomechanisms is suspected but not clearly identified. I propose that T cells are the missing piece of the puzzle for the synergistic effects of C9orf72 haploinsufficiency and DRP toxicity and will explore a) whether peripheral antigen-presenting cells (APCs) and CNS microglia present DPRs to prime antigen-specific T-cell response; b) whether C9orf72 haploinsufficiency alters antigen presentation of microglia and APCs; c) whether T cells mediate synergic effects of C9orf72 haploinsufficiency and DRP toxicity.
This novel project for the first time addresses peripheral and CNS activation of T cells against DPRs in C9orf72 ALS/FTD and reveals novel mechanism on synergistic effect of C9orf72 haploinsufficiency and DPR toxicity. It offers a unique integration of neurobiological tools, immunological methods, and single-cell-level approaches. It brings solid evidence on the antigen presentation of endogenous aggregating protein to drive antigen-specific T-cell response, which will broad the understanding on ALS/FTD and other neurodegenerative diseases.
It presents a promising research trajectory for the identification of new biomarkers, breakthrough therapeutic targets and the development of novel interventions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV | Bonn | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI